DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,163,819,619 | +1.0% | 4,690,917 | -2.3% | 0.41% | +8.3% |
| Q2 2023 | $1,152,832,918 | -0.6% | 4,803,459 | +4.4% | 0.38% | -9.6% |
| Q1 2023 | $1,159,891,485 | -0.3% | 4,602,014 | +4.9% | 0.42% | -7.2% |
| Q4 2022 | $1,163,951,474 | +0.1% | 4,385,317 | -2.6% | 0.45% | -1.5% |
| Q3 2022 | $1,162,771,000 | -1.5% | 4,501,797 | -3.3% | 0.45% | +8.6% |
| Q2 2022 | $1,180,485,000 | -8.1% | 4,656,373 | +6.4% | 0.42% | +6.9% |
| Q1 2022 | $1,283,889,000 | -3.9% | 4,376,941 | +7.8% | 0.39% | -3.2% |
| Q4 2021 | $1,335,605,000 | +4.7% | 4,059,465 | -3.1% | 0.40% | -2.7% |
| Q3 2021 | $1,275,180,000 | +17.1% | 4,188,621 | +3.3% | 0.42% | +14.0% |
| Q2 2021 | $1,088,546,000 | +27.6% | 4,056,290 | +7.0% | 0.36% | +14.5% |
| Q1 2021 | $852,868,000 | -0.8% | 3,789,164 | -2.1% | 0.32% | -5.6% |
| Q4 2020 | $859,545,000 | -0.8% | 3,869,384 | -3.9% | 0.34% | -12.9% |
| Q3 2020 | $866,900,000 | +24.3% | 4,025,918 | +2.1% | 0.39% | +14.8% |
| Q2 2020 | $697,358,000 | +19.3% | 3,944,109 | -6.5% | 0.34% | -1.5% |
| Q1 2020 | $584,323,000 | -4.3% | 4,219,359 | +6.1% | 0.34% | +17.5% |
| Q4 2019 | $610,481,000 | +4.8% | 3,977,746 | -1.4% | 0.29% | -5.2% |
| Q3 2019 | $582,735,000 | +1.6% | 4,035,107 | +0.5% | 0.31% | -0.6% |
| Q2 2019 | $573,628,000 | +9.8% | 4,014,063 | +1.4% | 0.31% | +3.7% |
| Q1 2019 | $522,461,000 | +56.6% | 3,958,060 | +22.3% | 0.30% | +15.1% |
| Q4 2018 | $333,674,000 | +3.3% | 3,236,459 | +8.9% | 0.26% | +12.1% |
| Q3 2018 | $323,013,000 | +14.5% | 2,972,738 | +4.0% | 0.23% | +6.0% |
| Q2 2018 | $282,029,000 | -2.7% | 2,857,696 | -3.5% | 0.22% | -1.4% |
| Q1 2018 | $289,951,000 | -2.9% | 2,961,715 | -7.9% | 0.22% | +2.3% |
| Q4 2017 | $298,505,000 | +11.6% | 3,215,707 | +3.1% | 0.22% | +7.5% |
| Q3 2017 | $267,572,000 | +5.0% | 3,119,520 | +3.3% | 0.20% | -2.4% |
| Q2 2017 | $254,777,000 | +2.6% | 3,019,091 | +4.0% | 0.21% | -2.4% |
| Q1 2017 | $248,286,000 | +15.9% | 2,902,919 | +5.5% | 0.21% | +5.5% |
| Q4 2016 | $214,272,000 | +2.8% | 2,752,551 | +3.5% | 0.20% | -5.2% |
| Q3 2016 | $208,515,000 | -21.2% | 2,660,151 | +1.6% | 0.21% | -24.4% |
| Q2 2016 | $264,458,000 | +11.2% | 2,618,509 | +4.4% | 0.28% | +6.1% |
| Q1 2016 | $237,919,000 | +0.3% | 2,508,101 | -1.7% | 0.26% | -1.9% |
| Q4 2015 | $237,096,000 | +18.5% | 2,552,672 | +8.7% | 0.27% | +9.8% |
| Q3 2015 | $200,109,000 | +0.7% | 2,348,463 | +1.2% | 0.24% | +4.7% |
| Q2 2015 | $198,713,000 | +3.2% | 2,321,732 | +2.4% | 0.23% | +1.3% |
| Q1 2015 | $192,580,000 | -2.9% | 2,268,288 | -2.0% | 0.23% | -1.3% |
| Q4 2014 | $198,428,000 | +9.7% | 2,315,042 | -2.8% | 0.23% | +7.4% |
| Q3 2014 | $180,909,000 | -13.0% | 2,381,015 | -9.9% | 0.22% | -10.3% |
| Q2 2014 | $208,010,000 | +3.4% | 2,641,418 | -1.6% | 0.24% | -0.8% |
| Q1 2014 | $201,232,000 | -5.5% | 2,683,905 | -2.7% | 0.24% | -5.4% |
| Q4 2013 | $212,943,000 | +11.3% | 2,758,995 | -0.0% | 0.26% | +2.4% |
| Q3 2013 | $191,340,000 | +9.1% | 2,759,436 | -0.4% | 0.25% | +4.1% |
| Q2 2013 | $175,316,000 | – | 2,770,096 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |